Liposomal anthracyclines for breast cancer

Joseph A. Sparano, Eric P. Winer

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Doxorubicin and other anthracyclines are an important class of agents for the treatment of early and advanced stage breast cancer, but produce substantial acute and chronic toxicities. One strategy for reducing anthracycline-associated toxicity is packaging them in liposomes. Liposomes are closed vesicular structures that envelop water-soluble molecules. They may serve as vehicles for delivering cytotoxic agents more specifically to tumor, and limit exposure of normal tissues to the drug. Liposomal anthracyclines are more effective and less toxic in a number of preclinical models compared with conventional anthracyclines. Several liposomal anthracyclines have been extensively studied in humans with a variety of cancer types, including TLC D-99 (Myocet; The Liposome Company, Elan Corporation, Princeton, NJ), liposomal daunorubicin (Daunoxome; NeXstar Pharmaceuticals, Inc, San Dimas, CA), and pegylated liposomal doxorubicin (Doxil; Alza Pharmaceuticals, Palo Alto, CA, Caelyx; Schering Corporation, Kenilworth, NJ). Although none of these agents are currently approved for the treatment of breast cancer in the United States, the liposomal doxorubicin preparations seem to have comparable activity and less cardiac toxicity than conventional doxorubicin. Furthermore, they have been safely combined with other cytotoxic agents, including cyclophosphamide, 5-fluorouracil, vinorelbine, paclitaxel, and docetaxel. Further studies will be required do determine their role in the treatment of breast cancer.

Original languageEnglish (US)
Pages (from-to)32-40
Number of pages9
JournalSeminars in Oncology
Volume28
Issue number4 SUPPL. 12
StatePublished - 2001

Fingerprint

Anthracyclines
Breast Neoplasms
Liposomes
Doxorubicin
Cytotoxins
docetaxel
Pharmaceutical Preparations
Daunorubicin
Poisons
Product Packaging
Paclitaxel
Fluorouracil
Cyclophosphamide
Neoplasms
Therapeutics
liposomal doxorubicin
Water

ASJC Scopus subject areas

  • Oncology

Cite this

Sparano, J. A., & Winer, E. P. (2001). Liposomal anthracyclines for breast cancer. Seminars in Oncology, 28(4 SUPPL. 12), 32-40.

Liposomal anthracyclines for breast cancer. / Sparano, Joseph A.; Winer, Eric P.

In: Seminars in Oncology, Vol. 28, No. 4 SUPPL. 12, 2001, p. 32-40.

Research output: Contribution to journalArticle

Sparano, JA & Winer, EP 2001, 'Liposomal anthracyclines for breast cancer', Seminars in Oncology, vol. 28, no. 4 SUPPL. 12, pp. 32-40.
Sparano, Joseph A. ; Winer, Eric P. / Liposomal anthracyclines for breast cancer. In: Seminars in Oncology. 2001 ; Vol. 28, No. 4 SUPPL. 12. pp. 32-40.
@article{e666abe9b30f4d5f8c760a4fe254db8e,
title = "Liposomal anthracyclines for breast cancer",
abstract = "Doxorubicin and other anthracyclines are an important class of agents for the treatment of early and advanced stage breast cancer, but produce substantial acute and chronic toxicities. One strategy for reducing anthracycline-associated toxicity is packaging them in liposomes. Liposomes are closed vesicular structures that envelop water-soluble molecules. They may serve as vehicles for delivering cytotoxic agents more specifically to tumor, and limit exposure of normal tissues to the drug. Liposomal anthracyclines are more effective and less toxic in a number of preclinical models compared with conventional anthracyclines. Several liposomal anthracyclines have been extensively studied in humans with a variety of cancer types, including TLC D-99 (Myocet; The Liposome Company, Elan Corporation, Princeton, NJ), liposomal daunorubicin (Daunoxome; NeXstar Pharmaceuticals, Inc, San Dimas, CA), and pegylated liposomal doxorubicin (Doxil; Alza Pharmaceuticals, Palo Alto, CA, Caelyx; Schering Corporation, Kenilworth, NJ). Although none of these agents are currently approved for the treatment of breast cancer in the United States, the liposomal doxorubicin preparations seem to have comparable activity and less cardiac toxicity than conventional doxorubicin. Furthermore, they have been safely combined with other cytotoxic agents, including cyclophosphamide, 5-fluorouracil, vinorelbine, paclitaxel, and docetaxel. Further studies will be required do determine their role in the treatment of breast cancer.",
author = "Sparano, {Joseph A.} and Winer, {Eric P.}",
year = "2001",
language = "English (US)",
volume = "28",
pages = "32--40",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 12",

}

TY - JOUR

T1 - Liposomal anthracyclines for breast cancer

AU - Sparano, Joseph A.

AU - Winer, Eric P.

PY - 2001

Y1 - 2001

N2 - Doxorubicin and other anthracyclines are an important class of agents for the treatment of early and advanced stage breast cancer, but produce substantial acute and chronic toxicities. One strategy for reducing anthracycline-associated toxicity is packaging them in liposomes. Liposomes are closed vesicular structures that envelop water-soluble molecules. They may serve as vehicles for delivering cytotoxic agents more specifically to tumor, and limit exposure of normal tissues to the drug. Liposomal anthracyclines are more effective and less toxic in a number of preclinical models compared with conventional anthracyclines. Several liposomal anthracyclines have been extensively studied in humans with a variety of cancer types, including TLC D-99 (Myocet; The Liposome Company, Elan Corporation, Princeton, NJ), liposomal daunorubicin (Daunoxome; NeXstar Pharmaceuticals, Inc, San Dimas, CA), and pegylated liposomal doxorubicin (Doxil; Alza Pharmaceuticals, Palo Alto, CA, Caelyx; Schering Corporation, Kenilworth, NJ). Although none of these agents are currently approved for the treatment of breast cancer in the United States, the liposomal doxorubicin preparations seem to have comparable activity and less cardiac toxicity than conventional doxorubicin. Furthermore, they have been safely combined with other cytotoxic agents, including cyclophosphamide, 5-fluorouracil, vinorelbine, paclitaxel, and docetaxel. Further studies will be required do determine their role in the treatment of breast cancer.

AB - Doxorubicin and other anthracyclines are an important class of agents for the treatment of early and advanced stage breast cancer, but produce substantial acute and chronic toxicities. One strategy for reducing anthracycline-associated toxicity is packaging them in liposomes. Liposomes are closed vesicular structures that envelop water-soluble molecules. They may serve as vehicles for delivering cytotoxic agents more specifically to tumor, and limit exposure of normal tissues to the drug. Liposomal anthracyclines are more effective and less toxic in a number of preclinical models compared with conventional anthracyclines. Several liposomal anthracyclines have been extensively studied in humans with a variety of cancer types, including TLC D-99 (Myocet; The Liposome Company, Elan Corporation, Princeton, NJ), liposomal daunorubicin (Daunoxome; NeXstar Pharmaceuticals, Inc, San Dimas, CA), and pegylated liposomal doxorubicin (Doxil; Alza Pharmaceuticals, Palo Alto, CA, Caelyx; Schering Corporation, Kenilworth, NJ). Although none of these agents are currently approved for the treatment of breast cancer in the United States, the liposomal doxorubicin preparations seem to have comparable activity and less cardiac toxicity than conventional doxorubicin. Furthermore, they have been safely combined with other cytotoxic agents, including cyclophosphamide, 5-fluorouracil, vinorelbine, paclitaxel, and docetaxel. Further studies will be required do determine their role in the treatment of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034835602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034835602&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 32

EP - 40

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 12

ER -